Time-to-onset and -resolution of adverse events before/after atomoxetine discontinuation in adult patients with ADHD

References

• National Institute for Health and Clinical Excellence (NICE) . National Clinical Practice Guideline Number 72 Attention deficit hyperactivity disorder: Diagnosis and management of ADHD in children, young people and adults. London: British Psychological Society & Royal College of Psychiatrists; 2009. Available from www.nice.org.uk/nicemedia/live/12061/42060/42060.pdf. Last accessed 14 August 2013.
   Google Scholar
• National Institute for Health and Clinical Excellence (NICE) . Review of Technology Appraisal 13 Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents. London: National Institute for Health and Clinical Excellence; 2006. Available from www.nice.org.uk/nicemedia/pdf/TA098guidance.pdf. Last accessed 14 August 2013.
   Google Scholar
• Kooij SJ , Bejerot S , Blackwell A , Caci H , Casas-Brugué M , Carpentier PJ , et al. European consensus statement on diagnosis and treatment of adult ADHD: the European network adult ADHD. BMC Psychiatry 2010;10:67.
   PubMed Web of Science ®Google Scholar
• Cortese S , Holtmann M , Banaschewski T , Buitelaar J , Coghill D , Danckaerts M , et al. European ADHD Guidelines Group . Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. J Child Psychol Psychiatry 2013;54:227–46.
   PubMed Web of Science ®Google Scholar
• Biederman J , Mick E , Surman C , Doyle R , Hammerness P , Kotarski M , Spencer T . A randomized, 3-phase, 34-week, double-blind, long-term efficacy study of osmotic-release oral system-methylphenidate in adults with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 2010;30:549–53.
   PubMed Web of Science ®Google Scholar
• Brams M , Weisler R , Findling RL , Gasior M , Hamdani M , Ferreira-Cornwell MC , et al. Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: randomized withdrawal design. J Clin Psychiatry 2012;73:977–83.
   PubMed Web of Science ®Google Scholar
• Camporeale A , Day KA , Ruff D , Arsenault J , Williams D , Kelsey DK . Profile of sexual and genitourinary treatment-emergent adverse events associated with atomoxetine treatment: a pooled analysis. Drug Saf 2013;36:663–71.
   PubMed Web of Science ®Google Scholar
• Michelson D , Buitelaar JK , Danckaerts M , Gillberg C , Spencer TJ , Zuddas A , et al. Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry 2004;43:896–904.
   PubMed Web of Science ®Google Scholar
• Nolan EE , Gadow KD , Sprafkin J . Stimulant medication withdrawal during long-term therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple tic disorder. Pediatrics 1999;103:730–7.
   PubMed Web of Science ®Google Scholar
• Upadhyaya H , Ramos-Quiroga JA , Adler LA , Williams D , Tanaka Y , Lane JR , et al. Maintenance of response after open-label treatment with atomoxetine hydrochloride in international European and non-European adult outpatients with attention-deficit/hyperactivity disorder: a placebo-controlled, randomized withdrawal study. Eur J Psychiatry 2013;27:187–205.
   Web of Science ®Google Scholar
• Kelsey DK , Sumner CR , Casat CD , Coury DL , Quintana H , Saylor KE , et al. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics 2004;114:e1–8.
   PubMed Web of Science ®Google Scholar
• Michelson D , Allen AJ , Busner J , Casat C , Dunn D , Kratochvil C , et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 2002;159:1896–901.
   PubMed Web of Science ®Google Scholar
• Michelson D , Faries D , Wernicke J , Kelsey D , Kendrick K , Sallee FR , et al. Atomoxetine ADHD Study Group . Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 2001;108:E83.
   PubMed Web of Science ®Google Scholar
• Spencer T , Heiligenstein JH , Biederman J , Faries DE , Kratochvil CJ , Conners CK , et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2002;63:1140–7.
   PubMed Web of Science ®Google Scholar
• Michelson D , Adler L , Spencer T , Reimherr FW , West SA , Allen AJ , et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 2003;53:112–20.
   PubMed Web of Science ®Google Scholar
• Spencer T , Biederman J , Wilens T , Prince J , Hatch M , Jones J , et al. Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry 1998;155:693–5.
   PubMed Web of Science ®Google Scholar
• Adler LA , Spencer T , Brown TE , Holdnack J , Saylor K , Schuh K , et al. Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial. J Clin Psychopharmacol 2009;29:44–50.
   PubMed Web of Science ®Google Scholar
• Buitelaar JK , Michelson D , Danckaerts M , Gillberg C , Spencer TJ , Zuddas A , et al. A randomized, double-blind study of continuation treatment for attention-deficit/hyperactivity disorder after 1 year. Biol Psychiatry 2007;61:694–9.
   PubMed Web of Science ®Google Scholar
• Newcorn JH , Michelson D , Kratochvil CJ , Allen AJ , Ruff DD , Moore RJ ; Atomoxetine Low-dose Study Group . Low-dose atomoxetine for maintenance treatment of attention-deficit/hyperactivity disorder. Pediatrics 2006;118:e1701–e6.
   PubMed Web of Science ®Google Scholar
• Eli Lilly and Company . Strattera (atomoxetine hydrochloride). package insert Indianapolis: IN: 2015.
   Google Scholar
• Camporeale A , Upadhyaya H , Ramos-Quiroga JA , Adler JA , Williams D , Tanaka Y , et al. Safety and tolerability of atomoxetine hydrochloride in a long-term, placebo-controlled randomized withdrawal study in European and non-European adults with attention-deficit/hyperactivity disorder. Eur J Psychiatry 2013;27:206–24.
   Web of Science ®Google Scholar
• Adler LA , Spencer TJ , Williams DW , Moore RJ , Michelson D . Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study. J Atten Disord 2008;12:248–53.
   PubMed Web of Science ®Google Scholar
• Stiefel G , Besag FM . Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder. Drug Saf 2010;33:821–42.
   PubMed Web of Science ®Google Scholar
• Adler LA , Wilens T , Zhang S , Dittmann RW , D’Souza DN , Schuh L , et al. Atomoxetine treatment outcomes in adolescents and young adults with attention-deficit/hyperactivity disorder: results from a post hoc, pooled analysis. Clin Ther 2012;34:363–73.
   PubMed Web of Science ®Google Scholar
• Wilens TE , Spencer TJ , Biederman J , Girard K , Doyle R , Prince J , et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry 2001;158:282–8.
   PubMed Web of Science ®Google Scholar
• Kielbasa W , Kalvass JC , Stratford R . Microdialysis evaluation of atomoxetine brain penetration and central nervous system pharmacokinetics in rats. Drug Metab Dispos 2009;37:137–42.
   PubMed Web of Science ®Google Scholar
• Young JL , Sarkis E , Qiao M , Wietecha L . Once-daily treatment with atomoxetine in adults with attention-deficit/hyperactivity disorder: a 24-week, randomized, double-blind, placebo-controlled trial. Clin Neuropharmacol 2011;34:51–60.
   PubMed Web of Science ®Google Scholar
• Wietecha LA , Ruff DD , Allen AJ , Greenhill LL , Newcorn JH . Atomoxetine tolerability in pediatric and adult patients receiving different dosing strategies. J Clin Psychiatry 2013;74:1217–23.
   PubMed Web of Science ®Google Scholar
• Pharmacia Limited . Edronax (reboxetine) 4 mg tablets: Summary of Product Characteristics. Kent: 2011.
   Google Scholar
• Wernicke JF , Adler L , Spencer T , West SA , Allen AJ , Heiligenstein J , et al. Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective placebo-controlled assessment. J Clin Psychopharmacol 2004;24:30–5.
   PubMed Web of Science ®Google Scholar
• Wernicke JF , Faries D , Girod D , Brown J , Gao H , Kelsey D , et al. Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Saf 2003;26:729–40.
   PubMed Web of Science ®Google Scholar
• Cooper WO , Habel LA , Sox CM , Chan KA , Arbogast PG , Cheetham TC , et al. ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med 2011;365:1896–904.
   PubMed Web of Science ®Google Scholar
• Habel LA , Cooper WO , Sox CM , Chan KA , Fireman BH , Arbogast PG , et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA 2011;306:2673–83.
   PubMed Web of Science ®Google Scholar
• Holick CN , Turnbull BR , Jones ME , Chaudry S , Bangs ME , Seeger JD . Atomoxetine and cerebrovascular outcomes in adults. J Clin Psychopharmacol 2009;29:453–60.
   PubMed Web of Science ®Google Scholar